Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos

Regulatory Affairs
Return to: PBR Home | Regulatory Affairs
Search Refinements
Search Results: Regulatory Affairs
1-15 of 3264 results
PlasmaTech's lead product candidates get FDA orphan drug and rare pediatric disease designations
PlasmaTech Biopharmaceuticals (PTBI), a biopharmaceutical company focused on gene therapy and plasma-based products for severe and life- threatening rare diseases announced that the US Food and Drug Administration (FDA) had granted both Orphan Drug Designation and Rare Pediatric Disease Designation for both of PlasmaTech Biopharmaceuticals' lead product candidates for the treatment of Sanfilippo Syndromes A and B.
Regulatory Affairs > News
Bristol-Myers gets amended FDA breakthrough therapy status for daclatasvir-based HCV regimen
By PBR Staff Writer
The US Food and Drug Administration (FDA) has amended a previously granted breakthrough therapy designation for Bristol-Myers Squibb's investigational daclatasvir and sofosbuvir combination to treat patients with hepatitis C (HCV).
Regulatory Affairs > News
FDA grants orphan drug status for Alnylam's Revusiran to treat TTR-mediated amyloidosis
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted orphan drug designation to Alnylam Pharmaceuticals' investigational RNAi therapeutic, revusiran, to treat transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis).
Regulatory Affairs > News
Sarepta to submit rolling NDA for eteplirsen to treat DMD
By PBR Staff Writer
US-based biopharmaceutical firm Sarepta Therapeutics has held a pre-new drug application (NDA) meeting with the US Food and Drug Administration (FDA) regarding its lead product candidate, eteplirsen, to treat duchenne muscular dystrophy (DMD).
Regulatory Affairs > News
Boehringer gets acceptance in Scotland for Trajenta-insulin combination to treat T2D
By PBR Staff Writer
The Scottish Medicines Consortium (SMC) has accepted Boehringer Ingelheim's Trajenta (linagliptin) in combination with insulin to treat adults with type 2 diabetes (T2D) to improve glycaemic control.
Regulatory Affairs > News
Therabron's CG100 gets EMA orphan drug status to prevent bronchopulmonary dysplasia
By PBR Staff Writer
US-based biotechnology firm Therabron Therapeutics has received orphan drug designation from the European Medicines Agency (EMA) for its lead product candidate, CG100, for the prevention of bronchopulmonary dysplasia (BPD).
Regulatory Affairs > News
Fibrocell gets FDA rare pediatric disease designation for FCX-007 to treat RDEB
Fibrocell Science (FCSC), an autologous cell and gene therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced that the US Food and Drug Administration (FDA) has granted rare pediatric disease designation for Fibrocell's lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
Regulatory Affairs > News
FDA grants fast track status for Merck's pancreatic cancer drug evofosfamide
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted fast track designation for Merck's evofosfamide to treat patients living with advanced pancreatic cancer.
Regulatory Affairs > News
Hemispherx Biopharma gets EMA orphan medicine designation for Ampligen to treat Ebola Virus Disease
Hemispherx Biopharma has announced that its European subsidiary, Hemispherx Biopharma Europe, received formal notification from the European Commission [EU/3/15/1480-EMA/OD/310/14] approving its Orphan Medicinal Product Application for Ampligen(R), an experimental therapeutic, to treat Ebola Virus Disease (EVD).
Regulatory Affairs > News
FDA grants QIDP and fast track status for Cidara's antifungal product candidate CD101 IV
Cidara Therapeutics, a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced that the US Food and Drug Administration (FDA) has designated the company’s lead antifungal product candidate, CD101 IV, as a Qualified Infectious Disease Product (QIDP) with Fast Track status.
Regulatory Affairs > News
Effective Supply Chain Mapping Studies
As a provider of monitoring and validation systems for regulated environments, Vaisala regulatory experts are often asked to help troubleshoot issues in pharmaceutical and medical device supply chains. In this article we answer three questions we often receive on how to perform mapping studies for regulated environments.
Regulatory Affairs > Press Releases
AbbVie gets FDA breakthrough therapy status for venetoclax to treat CLL
By PBR Staff Writer
AbbVie has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for its investigational medicine venetoclax to treat chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.
Regulatory Affairs > News
Retrophin gets FDA orphan drug status for RE-024 to treat PKAN
By PBR Staff Writer
US-based pharmaceutical firm Retrophin has received orphan drug from the US Food and Drug Administration (FDA) for RE-024 to treat pantothenate kinase-associated neurodegeneration (PKAN), a rare and lethal autosomal recessive neurodegenerative disorder.
Regulatory Affairs > News
Makindus gets European orphan drug status for MI-100 to treat Stargardt's disease
Makindus, a specialty pharmaceutical development company focused on ophthalmology announced that the European Medicines Agency (EMA) has granted orphan drug designation for their lead candidate, MI-100, for the treatment of Stargardt's Disease.
Regulatory Affairs > News
FDA grants tentative approval for Amerigen's generic Toviaz
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted tentative approval for Amerigen Pharmaceuticals' abbreviated new drug application (ANDA) for a generic version of Toviaz (Fesoterodine Fumarate Extended-release Tablets, 4mg and 8mg).
Regulatory Affairs > News

PBR Supplier Recommendations

ERT - Getting it done. Right.
ERT is a leading global provider of high-quality patient safety and efficacy endpoint data collection solutions for use by biopharmaceutical companies during clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle.... Regulatory Affairs > Suppliers
3R PHARMA CONSULTING - Reducing Regulatory Risk
3R PHARMA CONSULTING provides cost-effective, timely solutions to registration filings and challenges in pharmaceutical development strategies across Europe, the US and the rest of world. ... Regulatory Affairs > Suppliers
SHL Group - Pen Injectors, Autoinjectors and Inhaler Systems
SHL is a privately-owned developer, designer and manufacturer of advanced drug delivery devices.... Regulatory Affairs > Suppliers
NNIT - The Full Service IT Consultancy Dedicated to Life Sciences
NNIT specialises in using IT to optimise the complex processes inherent in the life sciences industry. We are an international consultancy in the development, implementation, validation and operation of IT for the life sciences industry. ... Regulatory Affairs > Suppliers
7PSolutions - Climate Control Solutions
7PSolutions™ was founded in 2010 to fulfill an unmet need in the life sciences and transportation industries: a single solution for climate control, security and quality management through every stage of the supply chain. ... Regulatory Affairs > Suppliers
See more

PBR White Paper Recommendations

Specialised Project & Technology Transfer- Laboratory Equipment & Automated Systems By SHL Group
A US-based company dedicated to developing intelligent inspection solutions and equipment for the biotechnology, pharmaceutical, and medical device industries wanted to partner with an established manufacturer, possessing design and engineering capabilities as well as appropriate in-house quality systems. With lab equipment that finds defects in medical syringes, vials, cartridges, test tubes, and other medical containers, it was vital for the manufacturing partner to have ISO13485 and ISO9001 quality systems in place.... Regulatory Affairs > White Papers Design-To-Build – Laboratory Handling Equipment By SHL Group
A leading high-end laboratory handling and diagnostics equipment manufacturing company devoted to helping scientists meet challenges regularly faced in the lab, approached SHL Technologies with a request to develop benchtop laboratory tube array handling equipment. This equipment had to be available in a modular set-up and capable of pick-and-place sorting, weight measurement, and barcode reading.... Regulatory Affairs > White Papers Complex Module Manufacturing – IC testing Devices By SHL Group
An established manufacturer of Integrated Circuit (IC) testing equipment from Germany was following a global sourcing initiative and needed to search for a suitable supplier in Asia that had experience in manufacturing and offered strong production capabilities. Sustaining high quality manufacturing in an environment with established quality systems was vital to the manufacturer and became one of the key determining factors when choosing the right supplier.... Regulatory Affairs > White Papers Specialised Project & Technology Transfer – Precision Neurosurgical Equipment By SHL Group
An established manufacturer of Integrated Circuit (IC) testing equipment from Germany was following a global sourcing initiative and needed to search for a suitable supplier in Asia that had experience in manufacturing and offered strong production capabilities. Sustaining high quality manufacturing in an environment with established quality systems was vital to the manufacturer and became one of the key determining factors when choosing the right supplier.... Regulatory Affairs > White Papers Supply Chain Management – Surface Mount Technology & Solar Cell Manufacturing By SHL Group
A leading provider of screen printing equipment located in the UK with an established presence in China was looking for a manufacturing partner that was capable of taking over their supply chain management while maintaining international quality standards. With markets largely located in Asia, the company hoped to find a partner within the region that not only possessed the key manufacturing capabilities required, but one that could also offer western style management to ensure that the technology transfer would go smoothly.... Regulatory Affairs > White Papers See more
1-15 of 3264 results